Wellington Management Group LLP Purchases 412,399 Shares of PROCEPT BioRobotics Corporation $PRCT

Wellington Management Group LLP raised its holdings in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 47.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,274,004 shares of the company’s stock after buying an additional 412,399 shares during the period. Wellington Management Group LLP’s holdings in PROCEPT BioRobotics were worth $28,767,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of PRCT. BlackRock Inc. bought a new stake in shares of PROCEPT BioRobotics during the 2nd quarter worth approximately $109,961,000. Alliancebernstein L.P. increased its stake in PROCEPT BioRobotics by 58.6% in the third quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock worth $122,052,000 after purchasing an additional 1,262,928 shares during the period. T. Rowe Price Investment Management Inc. increased its stake in PROCEPT BioRobotics by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock worth $102,919,000 after purchasing an additional 1,218,815 shares during the period. Mackenzie Financial Corp lifted its position in shares of PROCEPT BioRobotics by 8.2% during the fourth quarter. Mackenzie Financial Corp now owns 1,573,405 shares of the company’s stock worth $49,512,000 after purchasing an additional 118,971 shares during the last quarter. Finally, Artisan Partners Limited Partnership boosted its stake in shares of PROCEPT BioRobotics by 11.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 1,520,700 shares of the company’s stock valued at $47,841,000 after purchasing an additional 155,601 shares during the period. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Larry Wood bought 23,900 shares of the company’s stock in a transaction on Friday, August 7th. The shares were acquired at an average price of $20.85 per share, with a total value of $498,315.00. Following the transaction, the chief executive officer owned 23,900 shares of the company’s stock, valued at $498,315. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 1,000 shares of company stock worth $28,480 in the last ninety days. 4.00% of the stock is owned by corporate insiders.

Key PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: The stock’s increase suggests investors may be treating the latest announcements as repetitive legal notices rather than a new deterioration in the company’s business. The reports did not announce a judgment, settlement, regulatory penalty, or additional financial charge.
• Neutral Sentiment: Multiple firms—including Kaplan Fox class action deadline Kaplan Fox, Hagens Berman investor deadline Hagens Berman, and Rosen Law investor deadline Rosen Law—reminded investors that September 22, 2026 is the deadline to seek lead-plaintiff status. The proposed class covers purchases made from February 28, 2024, through February 25, 2026.
• Negative Sentiment: The lawsuit alleges that PROCEPT made misleading statements or failed to disclose repeated weakness in unit handpiece sales and excess customer inventory, allegedly caused in part by late-quarter bulk discounts. Law firms say these issues contributed to a substantial stock decline, including an approximately 18% drop cited in the filings. The allegations remain unproven, but continued litigation could increase costs, management distraction, and investor uncertainty. Hagens Berman securities fraud lawsuit

Wall Street Analysts Forecast Growth

PRCT has been the topic of several recent analyst reports. TD Cowen reduced their price target on shares of PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating on the stock in a research note on Wednesday, August 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Friday, July 17th. Wells Fargo & Company lowered shares of PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 target price on the stock. in a research report on Wednesday, August 5th. Evercore set a $23.00 price target on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $20.00 price target on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $25.09.

PROCEPT BioRobotics Stock Up 6.5%

NASDAQ:PRCT opened at $22.76 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35. PROCEPT BioRobotics Corporation has a 1-year low of $16.67 and a 1-year high of $41.51. The company has a 50-day moving average of $20.35 and a 200 day moving average of $23.69. The firm has a market cap of $1.30 billion, a PE ratio of -11.73 and a beta of 0.91.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The business had revenue of $94.50 million during the quarter, compared to analysts’ expectations of $92.77 million. During the same period in the previous year, the company posted ($0.35) EPS. PROCEPT BioRobotics’s revenue for the quarter was up 19.3% on a year-over-year basis. As a group, research analysts anticipate that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current fiscal year.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.